Home > Boards > US OTC > Biotechs >

Galectin Therapeutics Inc. (GALT)

GALT RSS Feed
Add GALT Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 10/15/2019 12:05:56 AM - Followers: 84 - Board type: Free - Posts Today: 0

Galectin Therapeutics is a biotechnology company focused on discovery and development. We apply our leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer. Drug candidates based on our unique carbohydrate technology target galectin proteins, which are key mediators of biologic and pathologic function.

Galectin Therapeutics is pursuing therapies for indications in which galectins have a demonstrated role in the pathogenesis of a particular disease. We focus on diseases with serious, life-threatening consequences to patients, and those where current treatment options are limited. Our strategy is to establish clinical development approaches that add value to the Company in the shortest time possible, and to seek partners as the program advances and requires much greater resources.

Galectin Therapeutics leverages extensive scientific and development expertise as well as established relationships with outside sources to achieve cost effective and efficient development. We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis and cancer immunotherapy.
 

Galectin Therapeutics is pursuing therapies for indications in which galectins have a demonstrated role in the pathogenesis of a particular disease. We focus on diseases with serious, life-threatening consequences to patients, and those where current treatment options are limited. Though we do not have any current marketed products, our research and development programs, designed to ultimately help patients and their physicians, are focused on:

 

Fibrosis

 

Fibrosis is the development of excess fibrous connective tissue in an organ when exposed to a chronic disease. The longer the disease affects the organ, the more fibrous tissue is deposited and this ultimately results in the failure of the organ. Galectin Therapeutics’ drug candidates provide a promising and exciting new approach for the treatment of fibrotic diseases, including liver, lung and kidney fibrosis. Significant unmet need exists for treatment options in fibrosis. For example, there are currently no approved medical treatments available for the millions of patients in the U.S. who have non-alcoholic steatohepatitis with advanced fibrosis – commonly known as fatty liver disease. Learn about fibrosis and our research in this area including galectin effects on liver fibrosis, lung fibrosis and kidney fibrosis.

 

Cancer

 

Cancer harms the body when damaged cells divide uncontrollably to form lumps or masses of tissue called tumors. Research shows the potential for galectin inhibition to play an important role in cancer therapy, particularly tumor immunotherapy – an emerging treatment that enhances the activity of the immune system against cancer cells. There are more than 100 types of cancers, and for many of these cancers, few treatment options exist. Our drug candidates provide a new and complimentary approach to other drugs on the market for the treatment of cancer. Learn more about cancer and immunotherapy.

 

GALT
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
GALT News: Proxy Statement (definitive) (def 14a) 10/17/2019 08:01:26 AM
GALT News: Statement of Changes in Beneficial Ownership (4) 10/15/2019 07:02:09 AM
GALT News: Current Report Filing (8-k) 09/27/2019 08:30:56 AM
GALT News: Galectin Therapeutics, Inc. and Providence Cancer Institute Receive Patent on the Use of Belapectin (GR-MD-02) in Cancer Immu... 09/17/2019 08:00:00 AM
GALT News: Current Report Filing (8-k) 09/17/2019 07:51:17 AM
PostSubject
#3632   Is no one interested ? It appears buckysherm 10/15/19 12:05:56 AM
#3631   75 days would be .... tomorrow ? Sweet dreams. buckysherm 10/15/19 12:04:44 AM
#3630   Here are NASH-CX trial protocol guidelines for P3 Amatuer17 10/14/19 08:11:26 PM
#3629   Interesting report - out of $18 B potential Amatuer17 10/14/19 07:53:07 PM
#3628   The First step is the notice to proceed Chess Master 10/11/19 09:31:57 AM
#3627   I am hoping something like this deal - Amatuer17 10/07/19 01:30:18 PM
#3626   I got from the business update Galectin Therapeutics Reports Amatuer17 10/07/19 01:26:51 PM
#3625   I see no news to support a 9% jimmy667 10/07/19 12:23:24 PM
#3624   It looks like some are buying the rumour jimmy667 10/07/19 12:18:20 PM
#3623   The phase 3 protocol was submitted on Aug Amatuer17 10/02/19 04:39:47 PM
#3622   This is long term play if they go Amatuer17 09/13/19 05:12:49 AM
#3621   Test buckysherm 09/12/19 02:17:28 PM
#3620   LOL $1 - $2 stock_observer_77 09/09/19 08:58:52 AM
#3619   Thanks for your insight. You sound like a mikeslife 09/09/19 08:54:57 AM
#3618   I bought 5,000 shares of GALT around this Scapes 09/09/19 03:05:50 AM
#3617   This stock Has My Attention . Pennyzilla 08/26/19 04:35:45 PM
#3616   The science hasn’t helped CYDY. That’s why buckysherm 08/23/19 11:53:21 AM
#3615   They are clearly going to have another update Chess Master 08/18/19 10:38:55 PM
#3614   Galectin Therapeutics a Potential $10 Billion Buyout, still valid? Unoqualunque 07/31/19 08:38:03 AM
#3613   Biotechs' Second-Half Battle stockguard 07/22/19 03:16:28 PM
#3612   Agree - they are ahead of everyone in Amatuer17 07/21/19 07:42:01 PM
#3611   I’m almost as disappointed in GALT as I buckysherm 07/21/19 03:59:55 PM
#3610   So the P2 results were available last year, Amatuer17 07/19/19 06:36:12 AM
#3609   The field of company`s is thinning out now. stockguard 06/29/19 10:31:51 AM
#3608   They are in Nash fibrosis not CX Amatuer17 06/27/19 05:42:46 PM
#3607   And Genfit buckysherm 06/27/19 03:42:52 PM
#3606   Exactly (-; stockguard 06/26/19 06:17:51 PM
#3605   So CNAT failed in NASH-CX , who is Amatuer17 06/26/19 07:15:12 AM
#3604   Big pharma’s billion-dollar bets stockguard 06/14/19 04:20:30 PM
#3603   Are you ssying the article posted on seekingalpha Unoqualunque 05/22/19 02:22:57 AM
#3602   Nonsense stock_observer_77 05/20/19 12:37:03 PM
#3601   I am 99.999% sure the one who posted biotech2010 05/20/19 12:08:53 PM
#3599   New article about GALT on Seeking Alpha, puts Glycobio 05/20/19 11:17:58 AM
#3598   I just oversubscribed for an additional 40% above thefamilyman 05/17/19 02:19:53 PM
#3597   It was definitely wrong and corrected because I biotech2010 05/15/19 02:53:54 PM
#3596   Looks like they did have it wrong originally Phantom Lord 05/15/19 01:21:06 PM
#3595   I received an amended, corrected Rights Offer notification biotech2010 05/15/19 01:15:10 PM
#3594   STILL UNDERVALUED AT THIS PRICE microcapbiotech 05/10/19 03:17:06 PM
#3593   If I'm going to believe something it's the Phantom Lord 05/09/19 07:24:27 PM
#3592   The GALT press release clearly states that the biotech2010 05/09/19 06:58:08 PM
#3591   I can't confirm that is what Schwab sent Phantom Lord 05/09/19 05:15:01 PM
#3590   I'm not misreading anything, there is a discrepancy biotech2010 05/09/19 05:10:04 PM
#3589   You're misreading the prospectus. Phantom Lord 05/09/19 04:48:41 PM
#3588   Phantom Lord 05/09/19 04:33:46 PM
#3587   The offering I received through TD Ameritrade says jmh0602 05/09/19 03:17:46 PM
#3586   My math isn't wrong, I took what is biotech2010 05/09/19 03:04:30 PM
#3585   I believe your math is wrong. I just jmh0602 05/09/19 02:40:45 PM
#3584   Good Luck! stock_observer_77 05/09/19 09:27:57 AM
#3583   You and the rest who are participating in biotech2010 05/09/19 09:26:15 AM
#3582   That makes no sense. stock_observer_77 05/09/19 09:09:18 AM
PostSubject